Incluye referencias bibliográficas

Preface; Contents; Part I: Cyclic Nucleotide Microdomains; 1: Receptor-Cyclic Nucleotide Microdomains in the Heart; 1.1 Introduction; 1.2 Biosensors for cAMP and cGMP; 1.3 Mechanisms of Compartmentation in Microdomains; 1.4 Receptor-cAMP/cGMP Microdomain Visualization; References; 2: Membrane Microdomains and cAMP Compartmentation in Cardiac Myocytes; 2.1 Introduction; 2.2 Membrane Microdomains; 2.3 Receptor-Mediated Responses; 2.3.1 ß1-Adrenergic Receptors (ß1ARs); 2.3.2 ß2-Adrenergic Receptors (ß2ARs); 2.3.3 M2 Muscarinic Receptors (M2Rs); 2.3.4 Prostaglandin Receptors (EPRs)

2.4 Conclusions and Future DirectionsReferences; 3: Function to Failure: Compartmentalization of Cardiomyocyte Signaling by A-Kinase-­Anchoring Proteins; 3.1 Introduction; 3.2 AKAPs and Regulation of the Calcium Cycle; 3.2.1 AKAP7 (Small Isoforms); 3.2.2 AKAP7 (Large); 3.2.3 AKAP5 (AKAP75/AKAP79/AKAP150); 3.3 AKAPs and Cardiac Remodeling; 3.3.1 AKAP6; 3.3.2 AKAP13; 3.4 Other AKAPs with Characterized Functions; References; 4: Pharmacological Approaches for Delineating Functions of AKAP-­Based Signalling Complexes and Finding Therapeutic Targets; 4.1 Introduction

4.1.1 The cAMP Signalling Cascade4.1.2 cAMP Effectors; 4.1.3 cAMP Signalling Compartments; 4.2 A-Kinase Anchoring Proteins (AKAPs); 4.2.1 AKAP-PKA Interactions; 4.2.2 The Role of AKAPs in the Heart and Cardiovascular Diseases Exemplifies Their Potential Value as Drug Targets; 4.3 AKAP-PKA Disruptors; 4.3.1 Peptides; 4.3.1.1 Binding to R-Subunits of PKA; 4.3.1.2 Binding to AKB Domains of AKAPs; 4.3.1.3 Modified Peptides; 4.3.2 Peptidomimetics; 4.3.3 Small Molecules; 4.3.4 Disruptors of Interaction Between AKAPs and Proteins Other Than PKA; 4.4 Conclusions and Outlook; References

5: Chatting Second Messengers: PIP3 and cAMP5.1 Introduction; 5.2 PIP3: A Signaling Lipid on Membranes; 5.3 Mechanisms of Cross-Talk between PIP3 and cAMP Signaling; 5.3.1 PIP3-Mediated Downregulation of ß-AR/cAMP Signaling in Heart Failure; 5.3.2 PIP3- and PI3K-Dependent Control of cAMP Hydrolysis; 5.3.3 cAMP-Mediated Regulation of PIP3 Signaling; References; 6: Cyclic Nucleotide Phosphodiesterases and Compartmentation in Normal and Diseased Heart; 6.1 Introduction; 6.2 CN Signalling in Cardiac Myocytes; 6.3 Overview of the PDE Superfamily

6.4 Role of PDEs in Cyclic Nucleotide Compartmentation6.5 PDEs and Cyclic Nucleotide Compartmentation in Heart Failure; 6.6 PDEs as Therapeutic Targets in Ischemia/Reperfusion Injury?; 6.7 Concluding Remarks; References; 7: cAMP Compartmentalisation and Hypertrophy of the Heart: 'Good' Pools of cAMP and 'Bad' Pools of cAMP Coexist in the Same Cardiac Myocyte; 7.1 cAMP Signalling in the Heart; 7.2 Compartmentalisation of the cAMP Signalling Pathway; 7.3 Compartmentalisation of GPCRs and ACs; 7.4 PKA Compartmentalisation via AKAPs; 7.5 PDEs and cAMP Compartmentalisation

The book comprehensively presents new findings in cardiovascular research related to signaling microdomains in health and disease. Important second messengers such as cAMP, cGMP, calcium and their role in microdomain signaling are discussed. The book offers and explains methodical approaches and technical ways how to successfully analyze microdomain signaling, also in the context of disease. It further provides scientific perspectives and strategies that are based on the concept of signaling within microdomains and that can revolutionize pharmacology and eventually lead to the effective treatment of cardiovascular diseases in future. This book is written for scientists in cardiovascular research, pharmacology, molecular and cellular biology as well as medical doctors in cardiology, angiology and nephrology. .

Versión impresa